Summary
Mergeomics 2.0 is an updated, freely accessible web server for integrating multi-omics disease association data to derive biological pathways and identify key regulatory drivers of disease. The version 2.0 release includes substantial user interface improvements, expanded functional genomics and disease datasets, and a newly incorporated drug repositioning pipeline (PharmOmics) to predict therapeutics targeting identified disease processes. The tool is designed to reduce analytical workload whilst providing flexibility for diverse user-specific omics integration needs.
Regional applicability
As a freely accessible bioinformatics platform, Mergeomics 2.0 is globally applicable and would be available to UK-based researchers and clinicians seeking to integrate multi-omics data for disease pathway discovery. The tool's utility depends on its integration with UK-specific disease GWAS and functional genomics datasets, and its accessibility may support precision medicine initiatives in NHS research contexts.
Key measures
Analytical outputs from four core functions: Marker Dependency Filtering (MDF), Marker Set Enrichment Analysis (MSEA), Meta-MSEA, and Key Driver Analysis (KDA); drug repositioning predictions from PharmOmics pipeline
Outcomes reported
The study describes the development and features of Mergeomics 2.0, a web server that integrates multi-omics data to identify disease-relevant biological pathways, key regulatory drivers, and potential drug targets. The platform processes summary statistics from multiple omics association studies (GWAS, EWAS, TWAS, PWAS) and incorporates new functionality including an improved user interface, expanded datasets, and a drug repositioning pipeline (PharmOmics).
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.